干细胞之家 - 中国干细胞行业门户第一站

 

 

搜索
朗日生物

免疫细胞治疗专区

欢迎关注干细胞微信公众号

  
查看: 288800|回复: 247
go

异基因骨髓间充质细胞治疗缺血性脑卒中临床试验

Rank: 8Rank: 8

积分
68783 
威望
68783  
包包
182946  

论坛元老 优秀会员

发表于 2011-3-4 16:30 |显示全部帖子
A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With Ischemic Stroke. S- n3 T1 M( Z, U/ B  @6 M0 C
This study is currently recruiting participants.
' ]9 C6 c$ a7 s: ~1 E8 e1 HVerified by Stemedica Cell Technologies, Inc., February 2011
* a) G! q" F0 u2 n/ h. I. kFirst Received: February 10, 2011 Last Updated: February 15, 2011 History of Changes
0 j& H1 j% r" C( z
+ p- I' d/ Z8 [Sponsor:         Stemedica Cell Technologies, Inc.
. r% J! z  C3 z1 D7 VCollaborator:         University of California, San Diego& M( H4 ]$ D  k8 @1 s( T! d0 N$ P
Information provided by:         Stemedica Cell Technologies, Inc.9 }0 a# {4 S7 P# [
ClinicalTrials.gov Identifier:         NCT012974131 m3 B7 S) c  J" ^: i; ^$ a
  Purpose
. H: q- M4 a- W8 p! FThe purpose of this study is to assess the safety and tolerability of allogeneic adult mesenchymal bone marrow cells administered intravenously to patients with ischemic stroke.
- g# P: d( u3 WCondition # i% v/ i9 O" t' [
Intervention
9 L# w0 ?" g$ g& w0 y/ b: L9 mPhase
3 y: n$ J8 ], P6 b2 r1 \8 J1 E( R) _& j7 j6 a7 f
Ischemic Stroke        Biological: Allogeneic adult mesenchymal bone marrow stem cells        Phase I9 ^9 q* D5 O' Y% ]. b% D1 }
Phase II7 O0 p+ E. i$ D3 ]# w: E+ z
. M) D1 A! L6 j
Study Type:        # J' O" @! |* c8 [
Interventional
) g* }+ V4 q" hStudy Design:        Allocation:Non-Randomized* Q+ h  v) \: K! B
Control:Uncontrolled3 k. ?* U: d6 z
Endpoint Classification:Safety/Efficacy Study
5 p4 d$ R# A& ~7 ^) G) M' vIntervention Model:Single Group Assignment( m; Q( m) s9 c8 s: I& n
Masking:Open Label* ?3 ^. j. p, D0 q: |+ ^. r
Primary Purpose:Treatment# t6 b  Q% }  \/ l$ C
Official Title:        A Phase I/II, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Ischemic Stroke
8 [; _3 v2 f& k1 u" }
2 b5 L& O; Q; A- kFurther study details as provided by Stemedica Cell Technologies, Inc.:; d% W2 a1 L5 ]; @* i, t3 j. {9 J. d
" R1 A" F( t* [. Y& C
Primary Outcome Measures: ! i0 I- D" L3 F
•        The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period. [Time Frame:12 month] [Designated as safety issue:Yes] 3 v( s7 S  k; x; z
The primary endpoint will be the safety of treatment with aMBMC during the twelve-month study period as determined by the incidence and severity of adverse events, clinically-significant changes on clinical laboratory tests, vital signs, physical and neurologic examinations.
) ~& o/ U# S, Y8 {Secondary Outcome Measures: $ O; v( [# S4 O& m  o
•        National Institutes of Health Stroke Scale Score. [Time Frame:12 months] [Designated as safety issue:Yes]
& J& N6 m3 X( E* q# }3 K/ UThe change from the baseline in National Institutes of Health Stroke Scale score will be calculated at 1, 3, 6, 9, 12 months post-treatment, as available:
  W# L% p, G0 F+ N9 D$ w: g•        Mini Mental Status Exam score. [Time Frame:12 month] [Designated as safety issue:Yes]
/ n. G8 ~2 m! f: p0 ?% J' r3 YThe change from the baseline in Mini Mental Status Exam score will be calculated at 1, 3, 6, 9, 12 months post-treatment, as available.
; K( K. l/ @- U; X0 L0 {•        Barthel Index Score. [Time Frame:12 month] [Designated as safety issue:Yes] / U- C& k* U9 Y( S
The change from the baseline in Barthel Index score at 1, 3, 6, 9, 12 months post-treatment, as available.
! w7 w7 u9 J+ Y, O•        The Geriatric Depression Scale Score. [Time Frame:12 month] [Designated as safety issue:Yes]
7 B& l  m9 B7 `, W8 q7 XThe change from baseline in the Geriatric Depression Scale score at 1, 3, 6, 9, 12 months post-treatment, as available.
3 {" z7 A# O& d4 h& }8 [* ]8 n& r7 K
Estimated Enrollment:        35# P1 h0 w" N8 V, F* l( E
Study Start Date:        February 2011$ U; l6 l2 B( R
Estimated Study Completion Date:        February 2013
  j  J5 U# I! O, A0 I  Y- JEstimated Primary Completion Date:        May 2012 (Final data collection date for primary outcome measure)% h" u3 x! I4 }1 C0 Z
Arms
# u5 S  ~: n# B5 ?! b* `& EAssigned Interventions + T! @  G- a& z& B, e

' i: f( D) |: E+ e0 ?3 wStem cells: Experimental
/ v0 y- W; ~$ ^9 m  }All subjects will receive allogeneic adult mesenchymal bone marrow stem cells
' ]# S# x  B& U1 L# TIntervention: Biological: Allogeneic adult mesenchymal bone marrow stem cells        Biological: Allogeneic adult mesenchymal bone marrow stem cells
$ y! {: |/ m1 zPatients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells9 L" T  `0 g7 |$ g& z6 N3 z
' P/ e9 n9 Z, _! l
Detailed Description:
, h( k; q' z. ^' O* BStroke remains a major global healthcare problem. Recent data compiled by the American Heart Association (AHA) for 2008 show that the annual incidence of new or recurrent stroke in the United States is about 780,000, with approximately 600,000 of these strokes being first attacks. Among adults age 20 and older, the estimated prevalence of stroke in 2005 was 5.8 million in the United States, resulting in >150,000 deaths annually, with 4.8 million stroke survivors alive today. Stroke ranks as the country's third leading cause of death, behind only cancer and heart disease. The only approved treatments of acute ischemic stroke involve restoring blood flow to the affected region by using thrombolytics or mechanical devices that physically remove clots. However, the use of thrombolytics is limited due to the therapeutic window of < 3-6 hours post onset of stroke symptoms such that only a small fraction of stroke patients receive this therapy. Following the completion of a stroke, there is little therapy to offer patients to promote recovery other than physical, occupational, and speech therapy.% a+ d. Y$ e  {& S6 N' \5 k
Allogeneic mesenchymal stem cells have been used in a number of clinical trials for different indications demonstrated the safety of allogeneic mesenchymal stem cell treatment. In addition to their ability to differentiate into multiple different cell types that would be contributory to the recovery and repair of the brain by replacing destroyed cells, mesenchymal stem cells also secrete angiogenins, cytokines and trophic factors that can support and stimulate multiple other cell types. The cascade of cellular events following the release of these cytokines and trophic factors would also potentially lead to beneficial effects by restoring blood supply, by rescuing cells at risk, and by stimulating the remaining cell populations to repair and propagate new cells and synaptic connections.% P- w8 Z' H/ o
  Eligibility9 ~5 l0 G/ K3 f+ o7 n( c* k! Z
Ages Eligible for Study:         18 Years and older; J3 Q2 `5 @8 j( U; L# P
Genders Eligible for Study:          Both
" F% q( `" U1 v3 _3 e6 |Accepts Healthy Volunteers:           No
- \. h- Y' E- V9 _$ hCriteria
2 g0 c# ?9 V% ]" sInclusion Criteria:
8 d3 ?1 `) n" D9 v; e; _" f/ g7 g•        Clinical diagnosis of ischemic stroke for longer than 6 months ( W+ t( C: ]9 k% F' O  S: i
•        Brain CT/MRI scan at initial diagnosis and at enrollment consistent with ischemic stroke 2 A) r' A! v4 u6 I3 M, {! @
•        No substantial improvement in neurologic or functional deficits for the 2 months prior to enrollment
6 A( y9 l) s% U: Q1 n* v•        NIHSS score between 6-20
; o' Y# t  L6 n1 _; S3 o/ e•        Life expectancy greater than 12 months
6 C0 j! h6 R' j: a1 I: H1 D& {•        Prior to treatment patient received standard medical care for the secondary prevention of ischemic stroke
5 D; n8 I  p# f) m- Z% S& S7 R•        Adequate organ function as defined by the following criteria:   ^4 L6 y2 N4 l8 p0 G0 p
Exclusion Criteria:7 z. C" X, t8 y& Q: I
•        History of uncontrolled seizure disorder
% e; [& S  y: t* {# w* I" L$ s•        History of cancer within the past 5 years.
) {9 A( D6 T& i( F/ A$ Q/ L" Y•        History of cerebral neoplasm ! f5 t% J( K( I1 h8 e
•        Positive for hepatitis B, C or HIV + C% ^4 L4 ?! c0 F! T; j2 _& m: c
•        Myocardial infarction withing six months of study entry / ?! C1 ]: {7 c9 \0 d2 x8 ]; x
•        Findings on baseline CT suggestive of subarachnoid or intracerebral hemorrhage within past 12 months.
7 u$ I* K9 y( s- v( C- ?+ W; X•        Allergies to Bovine or Porcine products 0 j4 L' m2 {9 L8 d! y
  Contacts and Locations% K0 k7 \/ m  E
Please refer to this study by its ClinicalTrials.gov identifier: NCT012974135 I' E; P0 G7 D9 F# H
+ ^( N7 o+ t" A
Contacts! T8 N7 h0 ^6 l. \& E7 \0 O
Contact: Michael L Levy, MD, PhD FACS        858-966-8574       
& ^! ~% R- W+ D2 D* l$ i6 X# r* j5 F0 h
Locations6 Y# x$ O  m7 w6 S- u
United States, California
) J$ I5 ]% b* ]# I+ ?University of California San Diego Division of Neurological Surgery        Recruiting
5 W: j  M; z/ g. s2 L+ W4 JSan Diego, California, United States, 92123 ( d1 r2 ~/ l( P" X! [
Contact: Michael L Levy, MD, PhD FACS  858-966-8574
5 B0 s: L$ Y$ D4 d# {+ SPrincipal Investigator: Michael L Levy, MD, PhD FACS
8 T& {  m" j3 Y  G* h! I5 PSponsors and Collaborators
4 {! l- {9 z( f: \5 J$ }Stemedica Cell Technologies, Inc.% k7 T5 r: v- t% z3 s+ j9 Z
University of California, San Diego
7 _. U7 e* f( N$ W3 r* rInvestigators; i: t7 p1 b( E# u) W2 o
Study Director:        Lev Verkh, PhD        Stemedica Cell Technologies, Inc.. K6 ]" V5 f, [' f# m
  More Information
7 X$ g1 a& r. G8 g8 E  W0 g, N! @: {. ?
No publications provided
1 @7 l' K1 t$ ~4 J, r6 h. p) o1 E9 aResponsible Party:        Stemedica Cell Technologies, Inc. ( Lev Verkh, PhD Chief Regulatory & Clinical Development Officer )7 P- C! U* S6 P# h3 N( u
ClinicalTrials.gov Identifier:        NCT01297413  History of Changes
. s, A2 l# k5 A' |$ x. ?
8 k! ]2 W9 @2 F. R" }& z1 k' n1 j: W6 P" nOther Study ID Numbers:        STEM 101-M4 B  [" \  f( G8 [, N$ a- j) F
Study First Received:        February 10, 2011+ E/ k/ m: R2 E+ J- p
Last Updated:        February 15, 2011! j8 z" m4 a4 e) _7 C
Health Authority:        United States: Food and Drug Administration5 n! t) ]* F! h$ J  L

/ P% f( S7 ~+ @# ~1 S+ ]; LKeywords provided by Stemedica Cell Technologies, Inc.:
" m) S2 ^) k4 m, b1 @Allogeneic adult stem cells ischemic stroke        
  v( H  `+ r  x, c, k- Y: U2 V
9 I; b8 {, f! ?8 n9 F. b, K  _* nAdditional relevant MeSH terms:
$ ]4 R) X% L  Q8 D. m2 XIschemia
5 D. w$ h3 q, r# }" R- [Stroke
! ], z3 l1 n$ x# _- GCerebral Infarction
7 A8 b$ |* C( k: A7 x# GPathologic Processes
: `7 l9 |& q3 k) H# GCerebrovascular Disorders" R; a9 K7 N7 P1 Q# }, S  S! d
Brain Diseases        Central Nervous System Diseases
) H& k9 Q2 E2 V8 H' P% A$ \Nervous System Diseases2 M$ g$ @* [5 _" R& l$ `
Vascular Diseases" L. ~8 f. x2 {# C4 j( m
Cardiovascular Diseases' J" V2 B1 ]0 x. Y% l
Brain Infarction
8 I0 `4 l* b: ZBrain Ischemia& N4 u( a5 g3 @$ d9 N8 }, k
8 D& b# T' U6 y7 r1 J
ClinicalTrials.gov processed this record on February 28, 2011
, u* I1 c% N" S% n
& z& y, O" b' B/ V- F: `
已有 1 人评分威望 包包 收起 理由
细胞海洋 + 2 + 5 极好资料

总评分: 威望 + 2  包包 + 5   查看全部评分

Rank: 2

积分
61 
威望
61  
包包
1757  
发表于 2015-5-27 07:52 |显示全部帖子
照你这么说真的有道理哦 呵呵 不进沙子馁~~~  

Rank: 2

积分
64 
威望
64  
包包
1769  
发表于 2015-6-3 20:43 |显示全部帖子
回贴赚学识,不错了  

Rank: 2

积分
72 
威望
72  
包包
1942  
发表于 2015-7-2 15:49 |显示全部帖子
干细胞之家微信公众号
dddddddddddddd  

Rank: 2

积分
84 
威望
84  
包包
1877  
发表于 2015-7-26 08:33 |显示全部帖子
应该加分  

Rank: 2

积分
75 
威望
75  
包包
2118  
发表于 2015-7-26 17:49 |显示全部帖子
初来乍到,请多多关照。。。  

Rank: 2

积分
64 
威望
64  
包包
1769  
发表于 2015-7-28 17:57 |显示全部帖子
在线等在线等  

Rank: 2

积分
80 
威望
80  
包包
1719  
发表于 2015-7-29 10:27 |显示全部帖子
太棒了!  

Rank: 2

积分
75 
威望
75  
包包
2118  
发表于 2015-8-22 09:38 |显示全部帖子
先看看怎么样!  

Rank: 2

积分
75 
威望
75  
包包
2193  
发表于 2015-8-23 17:53 |显示全部帖子
每天早上起床都要看一遍“福布斯”富翁排行榜,如果上面没有我的名字,我就去上班……  
你需要登录后才可以回帖 登录 | 注册
验证问答 换一个

Archiver|干细胞之家 ( 吉ICP备2021004615号-3 )

GMT+8, 2024-10-7 00:42

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.